Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1903321110 | Oral cavity | LP | negative regulation of protein modification by small protein conjugation or removal | 45/4623 | 95/18723 | 1.31e-06 | 3.17e-05 | 45 |
GO:005117013 | Oral cavity | LP | import into nucleus | 65/4623 | 159/18723 | 4.78e-06 | 9.69e-05 | 65 |
GO:1901796110 | Oral cavity | LP | regulation of signal transduction by p53 class mediator | 42/4623 | 93/18723 | 1.31e-05 | 2.33e-04 | 42 |
GO:0045861110 | Oral cavity | LP | negative regulation of proteolysis | 122/4623 | 351/18723 | 1.32e-05 | 2.34e-04 | 122 |
GO:000660612 | Oral cavity | LP | protein import into nucleus | 62/4623 | 155/18723 | 1.76e-05 | 3.04e-04 | 62 |
GO:003298414 | Oral cavity | LP | protein-containing complex disassembly | 83/4623 | 224/18723 | 2.38e-05 | 3.86e-04 | 83 |
GO:1904667110 | Oral cavity | LP | negative regulation of ubiquitin protein ligase activity | 10/4623 | 12/18723 | 3.32e-05 | 5.02e-04 | 10 |
GO:190165317 | Oral cavity | LP | cellular response to peptide | 122/4623 | 359/18723 | 4.22e-05 | 6.10e-04 | 122 |
GO:0051444110 | Oral cavity | LP | negative regulation of ubiquitin-protein transferase activity | 13/4623 | 19/18723 | 7.20e-05 | 9.49e-04 | 13 |
GO:1901798110 | Oral cavity | LP | positive regulation of signal transduction by p53 class mediator | 15/4623 | 25/18723 | 1.83e-04 | 2.03e-03 | 15 |
GO:190336318 | Oral cavity | LP | negative regulation of cellular protein catabolic process | 33/4623 | 75/18723 | 1.96e-04 | 2.16e-03 | 33 |
GO:005143818 | Oral cavity | LP | regulation of ubiquitin-protein transferase activity | 25/4623 | 53/18723 | 3.12e-04 | 3.17e-03 | 25 |
GO:1904666110 | Oral cavity | LP | regulation of ubiquitin protein ligase activity | 13/4623 | 23/18723 | 1.09e-03 | 9.03e-03 | 13 |
GO:2000059110 | Oral cavity | LP | negative regulation of ubiquitin-dependent protein catabolic process | 22/4623 | 48/18723 | 1.14e-03 | 9.32e-03 | 22 |
GO:190305118 | Oral cavity | LP | negative regulation of proteolysis involved in cellular protein catabolic process | 27/4623 | 64/18723 | 1.57e-03 | 1.21e-02 | 27 |
GO:000218126 | Oral cavity | EOLP | cytoplasmic translation | 102/2218 | 148/18723 | 7.91e-60 | 4.74e-56 | 102 |
GO:000691323 | Oral cavity | EOLP | nucleocytoplasmic transport | 87/2218 | 301/18723 | 7.30e-16 | 4.37e-13 | 87 |
GO:005116923 | Oral cavity | EOLP | nuclear transport | 87/2218 | 301/18723 | 7.30e-16 | 4.37e-13 | 87 |
GO:007259425 | Oral cavity | EOLP | establishment of protein localization to organelle | 108/2218 | 422/18723 | 2.91e-15 | 1.45e-12 | 108 |
GO:190332026 | Oral cavity | EOLP | regulation of protein modification by small protein conjugation or removal | 73/2218 | 242/18723 | 1.41e-14 | 6.47e-12 | 73 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL23 | SNV | Missense_Mutation | | c.295N>C | p.Glu99Gln | p.E99Q | P62829 | protein_coding | deleterious(0.01) | possibly_damaging(0.794) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RPL23 | SNV | Missense_Mutation | novel | c.119T>G | p.Ile40Ser | p.I40S | P62829 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
RPL23 | SNV | Missense_Mutation | | c.11N>A | p.Arg4Gln | p.R4Q | P62829 | protein_coding | tolerated(0.19) | benign(0.328) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL23 | insertion | Nonsense_Mutation | novel | c.149_150insGTTCCTGGCCATCCCTTGATTTACAAATGTGATGTTGATTTGT | p.Asn50LysfsTer7 | p.N50Kfs*7 | P62829 | protein_coding | | | TCGA-A7-A0D9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
RPL23 | insertion | Frame_Shift_Ins | novel | c.116_117insGAAAGGTAGGAAATCAGTC | p.Ile39MetfsTer27 | p.I39Mfs*27 | P62829 | protein_coding | | | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
RPL23 | SNV | Missense_Mutation | novel | c.254N>A | p.Arg85Gln | p.R85Q | P62829 | protein_coding | tolerated(0.07) | benign(0.046) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RPL23 | SNV | Missense_Mutation | novel | c.397G>A | p.Ala133Thr | p.A133T | P62829 | protein_coding | deleterious(0.01) | benign(0.367) | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR |
RPL23 | SNV | Missense_Mutation | novel | c.107N>G | p.Asn36Ser | p.N36S | P62829 | protein_coding | tolerated(0.24) | benign(0.262) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL23 | SNV | Missense_Mutation | | c.213N>T | p.Glu71Asp | p.E71D | P62829 | protein_coding | tolerated(0.32) | benign(0.248) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL23 | SNV | Missense_Mutation | | c.172G>T | p.Gly58Cys | p.G58C | P62829 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D1-A17R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |